Plasma Testosterone: An Accurate Monitor of Hormone Treatment in Prostatic Cancer

Shearer, R. J.; Hendry, W. F.; Sommerville, Ian F.; Fergusson, J. D.

doi:10.1111/j.1464-410x.1973.tb12238.x

Cited by 159 publications

(43 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results have been obtained, with testosterone elevation observed in a minimal number of cases, after subcapsular orchiectomy [11,12], DES treatment [12] and after administration of goserelin 3-month depot [13]. As reported by the authors of this last study, the clinical condition of these patients was not impaired by the brief rise in serum testosterone.…”

Section: Discussionsupporting

confidence: 76%

Leuprorelin Three-Month Depot in the Treatment of Advanced and Metastatic Prostate Cancer: Long-Term Follow-Up Results

Jocham

1998

Urol Int

View full text Add to dashboard Cite

Objectives: To determine median survival time, median time to tumor progression and maintenance of testosterone suppression (i.e. ≤50 ng/dl) during long-term treatment with subcutaneous injections of leuprorelin acetate 3-month depot (LAD-3M). In Germany 62 patients with advanced prostate cancer participated in a prospective, randomized, multicenter phase II trial as part of a European study. Of these, 37 patients entered the follow-up study. Methods: Standard clinical investigations and methods were employed in the study. Results: Twenty-five of the 62 (40.3%) patients died during the course of the study. No death had a causal relationship with the study drug. Median survival time, median time to tumor progression and median period of progression-free survival were 1,149 (3.1 years), 1,015 (2.8 years) and 680 days (1.9 years), respectively. Adequate suppression of testosterone serum levels to the castration range was confirmed. Objective and subjective response as well as the safety profile were comparable to previously published results with LAD-3M, LAD-1M and other LHRH analogues. Conclusions: The results of this follow-up study confirm long-term efficacy and safety of LAD-3M for treatment in advanced prostate cancer. LAD-3M is a suitable alternative to the established shorter-acting LHRH-a depot formulations.

show abstract

Section: Discussionsupporting

confidence: 76%

Leuprorelin Three-Month Depot in the Treatment of Advanced and Metastatic Prostate Cancer: Long-Term Follow-Up Results

Jocham

1998

Urol Int

View full text Add to dashboard Cite

show abstract

“…On the other hand, even after total orchiectomy the highest values of testosterone in serum were measured at 135 ng/100 ml (135 ng/dl) [23]. A slight increase of testosterone may therefore not necessarily be due to insufficient suppression but may have its origin in extragonadal production of testosterone or active androgen metabolites [24].…”

Section: Discussionmentioning

confidence: 99%

An Evaluation of Pharmacokinetics and Pharmacodynamics of Leuprorelin Acetate 3M-Depot in Patients with Advanced and Metastatic Carcinoma of the Prostate

Khan

O'Brien

1998

Urol Int

View full text Add to dashboard Cite

Objectives: The investigational objectives of this open, noncomparative phase I study were to determine the pharmacokinetic profile of a single dose of 11.25 mg leuprorelin acetate, the effective duration of the chemical castration (serum testosterone ≤1.73 nmol/l) and safety in patients with locally advanced and/or metastatic carcinoma of the prostate foreseen for chemical castration, in the hope that such a dose of leuprorelin acetate may be suitable as a depot formulation to be administered 3-monthly to these patients. Methods: A total of 24 males up to 85 years old with histologically proven advanced carcinoma of the prostate were enrolled in the study to obtain 18 eligible patients. Each patient was given 11.25 mg of leuprorelin acetate in a depot formulation subcutaneously after reconstitution in 2 ml of a special suspension vehicle. The study period lasted 24 weeks. Patients whose serum testosterone levels reincreased prior to the end of the observation period of 24 weeks were withdrawn from the study and received the monthly depot formulation of 3.75 mg of leuprorelin acetate. Results: The 3M-depot formulation of leuprorelin acetate ensured continuous and constant drug release and effective suppression of testosterone serum levels to castration range for at least 13 weeks. After an initial rise, 5α-dihydrotestosterone as well as the gonadotropin serum levels of luteinizing hormone and follicular stimulating hormone reflected the testosterone serum pattern. Conclusion: The results of this study show that the 3M-depot preparation of leuprorelin acetate is effective in suppressing the serum testosterone levels to the castration range for a targeted period of at least 13 weeks.

show abstract

“…However, changes in plasma hormone levels are unrelated to both response and relapse. Patients may respond without effective testosterone suppression, and relapse despite testosterone levels in the castrate range (Shearer et al 1973). When patients are treated with more than 3 mg of diethylstilboestrol daily, serum testosterone is suppressed into the castrate range, FSH and LH decrease, whilst GH and prolactin increase (Boyne et al 1974).…”

Section: Hormone Receptorsmentioning

confidence: 99%

Hormonal Aspects of Prostatic Cancer: A Review

Waxman

1985

J R Soc Med

View full text Add to dashboard Cite

Plasma Testosterone: An Accurate Monitor of Hormone Treatment in Prostatic Cancer

Cited by 159 publications

References 10 publications

Leuprorelin Three-Month Depot in the Treatment of Advanced and Metastatic Prostate Cancer: Long-Term Follow-Up Results

Leuprorelin Three-Month Depot in the Treatment of Advanced and Metastatic Prostate Cancer: Long-Term Follow-Up Results

An Evaluation of Pharmacokinetics and Pharmacodynamics of Leuprorelin Acetate 3M-Depot in Patients with Advanced and Metastatic Carcinoma of the Prostate

Hormonal Aspects of Prostatic Cancer: A Review

Contact Info

Product

Resources

About